Literature DB >> 2737846

Dynamic management of squamous cell cancer of the anal canal.

N D Nigro1, V K Vaitkevicius, B Considine.   

Abstract

For many years the accepted treatment for squamous cell cancer of the anal canal has been abdominoperineal resection of the rectum. Recently, high dose radiation therapy has been advocated by some, and we initiated a study using a combination of radiation, chemotherapy and surgery. This review includes 44 patients treated by us from December 1971 to July 1983. We discontinued routine operation after 1975 because chemoradiation therapy eliminated the primary lesion in most patients. In fact, the gross lesion disappeared in 40 patients, 13 of whom had radical operations done on routine basis. Four operations were done for residual disease after chemoradiation treatment and one for local recurrence. The corrected, projected five year survival rate was 79% with a follow-up of at least four years in all patients. Most failures occurred in patients with large primary tumors, all of whom had radical operations after the preoperative therapy. This experience suggests that patients with primary lesions over 5 cm in maximum diameter should have an additional course of chemoradiation and/or abdominoperineal resection on a routine basis.

Entities:  

Mesh:

Year:  1989        PMID: 2737846     DOI: 10.1007/bf00178194

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  13 in total

1.  Pathology of anal cancer.

Authors:  B C Morson; L S Pang
Journal:  Proc R Soc Med       Date:  1968-06

2.  Combined chemotherapy, radiation, and surgery for epithelial cancer of the anal canal.

Authors:  W R Meeker; B J Sickle-Santanello; G Philpott; D Kenady; K I Bland; G H Hill; M B Popp
Journal:  Cancer       Date:  1986-02-01       Impact factor: 6.860

3.  Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy.

Authors:  B Cummings; T Keane; G Thomas; A Harwood; W Rider
Journal:  Cancer       Date:  1984-11-15       Impact factor: 6.860

4.  An evaluation of combined therapy for squamous cell cancer of the anal canal.

Authors:  N D Nigro
Journal:  Dis Colon Rectum       Date:  1984-12       Impact factor: 4.585

5.  Depth of invasion, location, and size of cancer of the anus dictate operative treatment.

Authors:  W H Schraut; C H Wang; P J Dawson; G E Block
Journal:  Cancer       Date:  1983-04-01       Impact factor: 6.860

6.  Carcinoma of the anal canal. A clinical and pathologic study of 188 cases.

Authors:  B M Boman; C G Moertel; M J O'Connell; M Scott; L H Weiland; R W Beart; L L Gunderson; R J Spencer
Journal:  Cancer       Date:  1984-07-01       Impact factor: 6.860

7.  Epidermoid cancer of the anorectum.

Authors:  D B Frost; P C Richards; E D Montague; G G Giacco; R G Martin
Journal:  Cancer       Date:  1984-03-15       Impact factor: 6.860

8.  A new approach to the management of epidermoid carcinoma of the anal canal.

Authors:  J Papillon; M Mayer; J F Montbarbon; J P Gerard; J L Chassard; C Bailly
Journal:  Cancer       Date:  1983-05-15       Impact factor: 6.860

9.  Effects of alpha-difluoromethylornithine and 5-fluorouracil on the proliferation of a human colon adenocarcinoma cell line.

Authors:  A N Kingsnorth; W E Russell; P P McCann; K A Diekema; R A Malt
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

10.  Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy.

Authors:  L Leichman; N Nigro; V K Vaitkevicius; B Considine; T Buroker; G Bradley; H G Seydel; S Olchowski; G Cummings; C Leichman
Journal:  Am J Med       Date:  1985-02       Impact factor: 4.965

View more
  6 in total

1.  Targeting Histone Demethylases: A New Avenue for the Fight against Cancer.

Authors:  Dante Rotili; Antonello Mai
Journal:  Genes Cancer       Date:  2011-06

2.  Combined chemoradiation therapy for anal cancer. A report of 56 cases.

Authors:  R Doci; R Zucali; L Bombelli; F Montalto; G Lamonica
Journal:  Ann Surg       Date:  1992-02       Impact factor: 12.969

3.  Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas.

Authors:  F B Cvitkovic; C Haie-Meder; V Papadimitrakopoulou; J P Armand; C Cioloca; N Maugis; J P Constans
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

Review 4.  Chromatin remodeling in cancer: a gateway to regulate gene transcription.

Authors:  Sujit S Nair; Rakesh Kumar
Journal:  Mol Oncol       Date:  2012-10-22       Impact factor: 6.603

5.  Anal canal carcinoma treatment results: the experience of a single institution.

Authors:  Mostafa El-Haddad; Raef S Ahmed; Abdallah Al-Suhaibany; Manal Al-Hazza; Nasser Al-Sanae; Alaa Abd Al-Jabbar; Samar Hamoud; Loay Ashaary; Shouky Bazerbashy; Khaled Balaraj
Journal:  Ann Saudi Med       Date:  2011 Mar-Apr       Impact factor: 1.526

6.  Molecular and genomic characterisation of a panel of human anal cancer cell lines.

Authors:  Alexander G Heriot; Robert G Ramsay; Wayne A Phillips; Glen R Guerra; Joseph C Kong; Rosemary M Millen; Matthew Read; David S Liu; Sara Roth; Shienny Sampurno; Joseph Sia; Maria-Pia Bernardi; Timothy J Chittleborough; Corina C Behrenbruch; Jiasian Teh; Huiling Xu; Nicole M Haynes; Jiaan Yu; Richard Lupat; David Hawkes; Natasha Di Costanzo; Richard W Tothill; Catherine Mitchell; Samuel Y Ngan
Journal:  Cell Death Dis       Date:  2021-10-18       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.